Los Angeles Capital Management LLC Akebia Therapeutics, Inc. Transaction History

Los Angeles Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$2.22 - $3.78 $58,941 - $100,359	-26,550 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$2.39 - $13.08 $29,420 - $161,014	12,310 Added 86.45%	26,550 $67,000
Q2 2020 Aug 05, 2020	BUY	$6.67 - $13.58 $94,980 - $193,379	14,240 New	14,240 $193,000
Q4 2018 Feb 11, 2019	SELL	$5.39 - $9.15 $181,400 - $307,943	-33,655 Closed	0 $0
Q3 2018 Nov 05, 2018	SELL	$7.44 - $10.65 $1.01 Million - $1.45 Million	-136,070 Reduced 80.17%	33,655 $297,000
Q2 2018 Jul 31, 2018	BUY	$9.15 - $11.34 $950,868 - $1.18 Million	103,920 Added 157.92%	169,725 $1.69 Million
Q1 2018 Apr 27, 2018	BUY	$9.53 - $15.68 $75,525 - $124,264	7,925 Added 13.69%	65,805 $627,000
Q4 2017 Feb 05, 2018	BUY	$14.24 - $19.59 $68,921 - $94,815	4,840 Added 9.13%	57,880 $861,000
Q3 2017 Nov 06, 2017	BUY	$13.06 - $19.67 $692,702 - $1.04 Million	53,040	53,040 $1.04 Million

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.